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Ethical Considerations of Ovarian and 
Testicular Tissue Cryopreservation in 
Pre-Pubertal Children Who Cannot Assent 
Katarina Lee† 
Introduction  
In the last two decades, fertility preservation options have 
become a part of medical treatment for individuals undergoing 
gonadotoxic treatments, most typically as a result of oncology 
therapy.1  However, the majority of studies and literature 
surrounding these procedures have focused on adults who have the 
ability to consent and pubertal children who have the ability to 
assent.  The ethical considerations of experimental pre-pubertal 
fertility cryopreservation techniques have not been adequately 
addressed.  The purpose of this Article is to argue that while parents 
and guardians normally have the best interests of their wards in 
mind when they make medical decisions, pre-pubertal fertility 
cryopreservation is ethically too problematic to permit parental or 
guardian consent without the child’s assent.  There are five parts to 
this Article: Part I will provide a background of the different fertility 
cryopreservation techniques available and their success rates; Part 
II will explain the guidelines governing pediatric experimental 
research; Part III will discuss informed consent and assent in the 
pediatric medical context; Part IV will provide the ethical 
arguments in opposition to pre-pubertal fertility cryopreservation 
without assent; and Part V will address the counter-arguments 
permitting pre-pubertal fertility cryopreservation without assent. 
I. Current Fertility Preservation Technologies 
There are several different fertility preservation techniques 
for those who are undergoing gonadotoxic treatments, including 
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 1. Anahad O’Connor, After Cancer, Fertility Is Often Within Reach, N.Y. TIMES: 
WELL (Sept. 23, 2013, 4:03 PM), http://well.blogs.nytimes.com/2013/09/23/after-
childhood-cancer-fertility-is-within-reach-for-many/?mcubz=1. 
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hormonal therapies, gonad shielding during treatments, and 
creative surgical techniques to prevent damage to the gonads.2  
These treatments are often less invasive than fertility 
cryopreservation techniques and as a result are less ethically 
controversial.  Additionally, both male and female pubertal patients 
may cryopreserve their mature gametes.  Sperm from male pubertal 
patients is either retrieved through ejaculation or when “ejaculation 
is not possible,” sperm may be retrieved through 
“electroejaculation, testicular biopsy, testicular sperm extraction, or 
epididymal sperm aspiration.”3  Ova from female pubertal patients 
are retrieved through a process of hormonally stimulating the 
ovaries to produce ova that are then aspirated from the ovary.4  
Patients may then cryopreserve their gametes independently while 
others may choose to create embryos with their gametes; 
afterwards, these embryos are cryopreserved. 
Female patients have the additional option of cryopreserving 
ovarian tissue, a procedure that is currently experimental.5  
Ovarian tissue cryopreservation entails removing either “part of an 
ovary or a whole ovary.”6  In partial ovarian tissue cryopreservation, 
the ovarian cortex, or “the ovary’s outer layer,”7 is removed, then 
sliced into small strips and cryopreserved.8  Eventually, these slices 
are thawed and placed back into the woman’s body so that she can 
conceive naturally.9  The benefit of cryopreserving ovarian tissue is 
that “[m]ost oocytes are located within the primordial follicles in the 
ovarian cortex; therefore, obtaining a small volume of cortical tissue 
potentially enables cryopreservation of large numbers of oocytes.”10  
 
 2. Stephanie J. Lee et al., ASCO Recommendation on Fertility Preservation in 
Cancer Patients: Guidelines Summary, 2 J. ONCOLOGY PRAC. 143, 143–44 (2006). 
 3. Am. Soc’y for Reprod. Med., Fertility Preservation and Reproduction in 
Patients Facing Gonadotoxic Therapies: A Committee Opinion, 100 FERTILITY & 
STERILITY 1224, 1226 (2013). 
 4. Tests and Procedures: In Vitro Fertilization (IVF), What You Can Expect, 
MAYO CLINIC, http://www.mayoclinic.org/tests-procedures/in-vitro-fertilization/
basics/what-you-can-expect/prc-20018905 (last visited Oct. 23, 2017). 
 5. Am. Soc’y for Reprod. Med., Ovarian Tissue Cryopreservation: A Committee 
Opinion, 101 FERTILITY & STERILITY 1237, 1237 (2014). 
 6. Fertility Preservation by Ovarian Tissue Banking (Ovarian Tissue Freezing), 
CTR. FOR HUMAN REPROD., https://www.centerforhumanreprod.com/services/fertility
-preservation/ovarian-tissue-freezing/ (last updated Nov. 15, 2014). 
 7. Id. 




 9. Id. 
 10. Am. Soc’y for Reprod. Med., supra note 5. 
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There have been successful pregnancies that have resulted from the 
re-transplantation of ovarian tissue,11 including one recent patient 
who underwent the procedure prior to puberty. 12  If total ovarian 
failure is anticipated, an entire ovary may be removed and 
cryopreserved.13  Notably, whole ovary cryopreservation is not as 
medically developed as partial ovarian tissue cryopreservation.  
There have not been any successful pregnancies resulting from a 
whole ovary being cryopreserved and then re-transplanted into the 
female.14  There has been a successful pregnancy from a whole ovary 
being donated to another woman15 and a successful pregnancy in 
which a whole ovary was removed, tissue was then removed from 
the ovary, and that tissue was then grafted to the woman’s 
remaining ovary.16 
The gametes of pre-pubertal patients cannot be retrieved 
through ejaculation or ova retrieval.17  As a result, the only means 
of fertility cryopreservation for female children is ovarian tissue 
cryopreservation, which is identical to pubertal ovarian tissue 
cryopreservation.18  The only option for male children is testicular 
tissue cryopreservation, as they are unable to produce semen and 
do not produce mature sperm.19  Pre-pubertal testicular tissue 
contains stem cells that have the possibility of becoming mature 
sperm.20  The idea is that the testicular tissue is either “reimplanted 
 
 11. Rob Stein, Freezing Ovaries Before Cancer Treatment May Preserve Fertility, 
NPR (Oct. 7, 2015, 2:29 PM), http://www.npr.org/sections/healthshots/2015/ 
10/06/446324220/freezing-ovaries-before-cancer-treatment-may-preserve-fertility 
(noting that Danish researchers found roughly one-third of participants who 
underwent the procedure succeeded in having a child). 
 12. Meera Senthilingam, Woman Is First to Have Baby with Ovaries Frozen in 
Childhood, CNN (Dec. 16, 2016, 3:40 PM), www.cnn.com/2016/12/15/health/first-
birth-from-frozen-ovarian-tissue/index.html. 
 13. Am. Soc’y for Reprod. Med., supra note 5, at 1238. 
 14. Freezing and Storing Eggs, HUMAN FERTILISATION & EMBRYOLOGY AUTH., 
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/46.html (last 
accessed Oct. 23, 2017). 
 15. James Randerson, Woman to Give Birth After First Ovary Transplant 
Pregnancy, THE GUARDIAN (Nov. 9, 2008, 7:52 AM), http://www.theguardian.com/ 
science/2008/nov/09/health; Sherman J. Silber, Gedis Grudzinskas & Roger G. 
Gosden, Successful Pregnancy After Microsurgical Transplantation of an Intact 
Ovary, 359 NEW ENG. J. MED. 2617, 2617 (2008). 
 16. Baby Born from Ovary Frozen in Mother’s Childhood, BBC NEWS, (June 10, 
2015), http://www.bbc.com/news/health-33063838. 
 17. Christine Wyns et al., Options for Fertility Preservation in Prepubertal Boys, 
16 HUMAN REPROD. UPDATE 312, 315 (2010). 
 18. Am. Soc’y for Reprod. Med., supra note 5. 
 19. Wyns, supra note 17, at 312–315. 
 20. Fertility Preservation Program, CHILDREN’S HOSP. OF PHILA., 
http://www.chop.edu/services/fertility-preservation-program#.VkYOb4RDm51 (last 
visited Nov. 21, 2017). 
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as is or matured” prior to transplantation back into the grown and 
healthy child.21  There has not been any proven success in humans, 
but animal studies have shown that testicular tissue can feasibly be 
removed and cryopreserved.22  The Fertility Preservation Program 
at The Children’s Hospital of Philadelphia (CHOP) is one of the 
most advanced and widely publicized centers in the United States 
providing these experimental treatments.23 
II. Experimental Treatment in Pediatrics 
These fertility cryopreservation techniques are experimental, 
meaning that children undergoing them should be protected by 
standard human research protocols for pediatrics.  As a result, 
clinicians have developed protocols in order to comply with ethical 
standards in pediatric clinical trials.24  In 2010, CHOP published its 
protocol for testicular tissue cryopreservation.25  Similarly, in 2012, 
the University of Pennsylvania, in conjunction with CHOP, the 
Oncofertility Consortium, and the National Physicians Cooperative, 
published a protocol for pre-pubertal ovarian tissue 
cryopreservation.26  Institutional Review Board (IRB) approval for 
pre-pubertal ovarian tissue cryopreservation was originally granted 
in April 2007 at the Hospital of the University of Pennsylvania 
(HUP) and in May 2009 at CHOP.27 
Generally, research that is either funded by federal dollars or 
performed by certain government agencies or individuals is subject 
 
 21. Id. 
 22. Id.; Honor Whiteman, Deep-Freezing Testicular Tissue Produces Healthy 
Baby Mice, MED. NEWS TODAY (July 2, 2014, 8:00 AM), 
http://www.medicalnewstoday.com/articles/279093.php. 
 23. Fertility Preservation Program, supra note 20.  Note that many premier 
hospitals have begun offering fertility preservation programs in recent years. 
 24. Jordan Reese, Penn Researchers Find Reproductive Germ Cells Survive and 
Thrive in Transplants, Even Among Species, U. PENN NEWS (Dec. 14, 2009), 
http://www.upenn.edu/pennnews/news/penn-researchers-find-reproductive-germ-
cells-survive-and-thrive-transplants-even-among-species. 
 25. J.P. Ginsberg et al., An Experimental Protocol for Fertility Preservation in 
Prepubertal Boys Recently Diagnosed with Cancer: A Report of Acceptability and 
Safety, 25 HUMAN REPROD. 37, 38 (2010). See PENN CTR. FOR BIOETHICS, THE PENN 
CENTER GUIDE IN BIOETHICS 335–36 (Vardit Ravitsky, Autumn Fiester & Arthur L. 
Caplan eds., 2009) (“If children cannot ejaculate or are too young, then testicular 
biopsy for sperm extraction or biopsy to use as germ cell repository can be done under 
IRB experimental conditions.”). 
 26. Clarisa R. Gracia et al., Ovarian Tissue Cryopreservation for Fertility 
Preservation in Cancer Patients: Successful Establishment and Feasibility of a 
Multidisciplinary Collaboration, 29 J. ASSISTED REPROD. & GENETICS 495, 495 
(2012). 
 27. Id. at 496. 
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to the Common Rule.28  The Common Rule, codified in the Code of 
Federal Regulations, requires human subjects research, including 
research conducted on children, to abide by specific guidelines and 
ethical standards.  Non-governmental institutions “that engage in 
human subject research that is conducted or supported by any U.S. 
federal department or agency that has adopted the Common Rule 
are required to”29 adopt the Federalwide Assurance (FWA).  This 
means, “an institution commits to HHS [Health and Human 
Services] that it will comply with the requirements in the HHS 
Protection of Human Subjects regulations at 45 CFR part 46 [The 
Common Rule].”30  A pre-requisite of receiving FWA designation is 
that the institution is required to designate an IRB to perform 
“ethical review of proposed research.”31  The University of 
Pennsylvania32 and CHOP33 have adopted the FWA; as a result, 
research conducted at these institutions is required to follow the 
federal guidelines. 
Using these federal guidelines, IRBs are to analyze pediatric 
experimental procedures under the following four categories:  (1) 
“[r]esearch not involving greater than minimal risk,”34 (2) 
“[r]esearch involving greater than minimal risk but presenting the 
prospect of direct benefit to the individual subjects,”35 (3) “[r]esearch 
involving greater than minimal risk and no prospect of direct 
benefit to the individual subjects, but likely to yield generalizable 
 
 28. 45 C.F.R. § 46.101 (2016); Federal Policy for the Protection of Human Subjects 
(‘Common Rule’), U.S. DEP’T. OF HEALTH & HUMAN SERVS.: OFFICE OF HUMAN 
RESEARCH PROTECTIONS, http://www.hhs.gov/ohrp/humansubjects/commonrule/
index.html (last visited Nov. 8, 2017); Stanley G. Korenman, TEACHING THE 
RESPONSIBLE CONDUCT OF RESEARCH IN HUMANS (RCRH) ch. 3 (2006), 
https://ori.hhs.gov/education/products/ucla/chapter2/page04b.htm (last accessed 
Nov. 8, 2017). 
 29. Jennifer S. Geetter & James W. Kim, OHRP Revises Federalwide Assurance, 
NAT’L L. REV. (July 14, 2011), http://www.natlawreview.com/article/ohrp-revises-
federalwide-assurance. 
 30. Federalwide Assurances (FWAs), U.S. DEP’T OF HEALTH & HUMAN SERVS., 
http://www.hhs.gov/ohrp/assurances/assurances/index.html (last visited Sept. 23, 
2017) (alteration in original). 
 31. OFFICE FOR HUMAN RESEARCH PROTS., U.S. DEP’T OF HEALTH & HUMAN 
SERVS., IRBS AND ASSURANCES, https://www.hhs.gov/ohrp/irbs-and-assurances.html 
(last visited Oct. 8, 2017). 
 32. Assurances, U PENN THE INSTITUTIONAL REVIEW BD., http://www.upenn.edu/
IRB/mission-institutional-review-board-irb/assurances (last visited Nov. 22, 2017) 
(hereinafter IRB GUIDEBOOK). 
 33. Federalwide Assurance (FWA): Compliance with Federal Regulatory 
Requirements and Guidelines, CHILDREN’S HOSP. OF PHILA. RESEARCH INST., 
https://irb.research.chop.edu/federalwide-assurance-fwa# (last visited Nov. 22, 
2017). 
 34. 45 C.F.R. § 46.404 (2016). 
 35. § 46.405. 
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knowledge about the subject’s disorder or condition,”36 and (4) 
“[r]esearch [that is] not otherwise approvable which presents an 
opportunity to understand, prevent, or alleviate a serious problem 
affecting the health or welfare of children.”37  Minimal risk “means 
that the probability and magnitude of harm or discomfort 
anticipated in the research are not greater in and of themselves 
than those ordinarily encountered in daily life or during the 
performance of routine physical or psychological examinations or 
tests.”38  The Institute of Medicine (IOM) has defined greater than 
minimal risk to be “a slight increase in the potential for harms or 
discomfort beyond minimal risk.”39  Additionally, IOM has defined 
direct benefit as “a tangible positive outcome,” for example, “cure of 
disease, relief of pain, and increased mobility.”40 
In all four categories, IRBs are required to make sure 
“[a]dequate provisions are made for soliciting the assent of the 
children and permission of their parents or guardians.”41  
Additionally, for research in Category 2, the following two 
requirements are needed:  “(a) [t]he risk is justified by the 
anticipated benefit to the subjects; [and] (b) [t]he relation of the 
anticipated benefit to the risk is at least as favorable to the subjects 
as that presented by available alternative approaches.”42  For 
research in Category 3, the following are required: 
(a) [t]he risk represents a minor increase over minimal risk; 
(b) [t]he intervention or procedure presents experiences to 
subjects that are reasonably commensurate with those 
inherent in their actual or expected medical . . . situations; 
[and] 
(c) [t]he intervention or procedure is likely to yield 
generalizable knowledge about the subjects’ disorder or 
 
 36. § 46.406. 
 37. § 46.407; ROBIN LEVIN PENSLAR, PROTECTING HUMAN RESEARCH SUBJECTS: 
INSTITUTIONAL REVIEW BOARD GUIDEBOOK ch. 6, 19–21 (2nd ed. 1993); Michelle 
Roth-Cline et al., Ethical Considerations in Conducting Pediatric Research, in 
PEDIATRIC CLINICAL PHARMACOLOGY (Hannsjörg W. Seberth, Anders Rane & 
Matthias Schwab eds. 2011) 219, 225–30. 
 38. § 46.102(i). 
 39. Paul Litton, Non-Beneficial Pediatric Research and the Best Interests 
Standard: A Legal and Ethical Reconciliation, 8 YALE HEALTH POL’Y ETHICS 359, 
377 (2008) (quoting COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, INST. OF 
MED., THE ETHICAL CONDUCT OF CLINICAL RESEARCH INVOLVING CHILDREN 17 
(Marilyn J. Field & Richard E. Berman eds., 2004)). 
 40. COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, INST. OF MED., THE 
ETHICAL CONDUCT OF CLINICAL RESEARCH INVOLVING CHILDREN 132 (Marilyn J. 
Field & Richard E. Berman eds., 2004) [hereinafter CLINICAL RESEARCH INVOLVING 
CHILDREN].  
 41. § 46.404–07.  
 42. § 46.405 (alteration in original). 
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condition which is of vital importance . . . [to] 
ameliorat[ing] [the] . . . disorder.43 
Lastly, for research in Category 4, the IRB must “find[] that 
the research presents a reasonable opportunity to further the 
understanding, prevention, or alleviation of a serious problem 
affecting the health or welfare of children” and the Secretary, after 
significant review, finds the research permissible.44 
III. Informed Consent and Assent in Pediatric Patients 
Informed consent in pediatric patients can create significant 
legal and ethical concerns.  Parents and guardians are legally able 
to consent and make decisions for their wards provided these 
medical decisions are in the best interests of the child.45  Under the 
legal doctrine of parens patriae, the state has the authority to take 
action to protect children if a parent or guardian “demonstrably 
act[s] contrary to [the best] interests of the child.”46  As Professor 
Anne Tamar-Mattis states: 
The basis for parental control over the medical decisions for 
treatment of children is two-fold.  It arises out of both the 
concept of a constitutional right to family privacy and the legal 
presumption that parents are best situated to make good 
decisions because “natural bonds of affection lead parents to act 
in the best interests of their children.”47 
Parents have been given significant deference to make medical 
decisions for their children as a result of the legal and social 
upholding of autonomous parenting.48  However, disagreements do 
 
 43. § 46.406.  
 44. § 46.407.  
 45. Jennifer L. Rosato, Using Bioethics Discourse to Determine When Parents 
Should Make Health Care Decisions for Their Children: Is Deference Justified?, 73 
TEMP. L. REV. 1, 7–8  (2000); Mary Koll, Growth, Interrupted: Nontherapeutic Growth 
Attenuation, Parental Medical Decision Making, and the Profoundly 
Developmentally Disabled Child’s Right to Bodily Integrity, 2010 U. ILL. L. REV. 225, 
243 (2010).  
 46. J. Steven Svoboda, Robert S. Van Howe & James G. Dwyer, Informed 
Consent for Neonatal Circumcision: An Ethical and Legal Conundrum, 17 J. 
CONTEMP. HEALTH L. & POL’Y 61, 84 (2000).  
 47. Anne Tamar-Mattis, Exceptions to the Rule: Curing the Law’s Failure to 
Protect Intersex Infants, 21 BERKELEY J. GENDER L. & JUST. 59, 79 (2006) (quoting 
Parham v. J. R., 442 U.S. 584, 602 (1979)).  Opinions differ regarding the use of the 
best interests standard in pediatric experimental research.  See Doriane Lambelet 
Coleman, The Legal Ethics of Pediatric Research, 57 DUKE L. J. 517, 609–10 (2007) 
(explaining how a balance between child protection and parents’ consent is the right 
approach); Seema Shah, Does Research with Children Violate the Best Interests 
Standard? An Empirical and Conceptual Analysis, 8 NW. J. L. & SOC. POL’Y 121, 
165–66 (2013) (arguing that a child’s interest should not be absolute, but rather that 
the value of research and the public good should also matter). 
 48. Lee Black, Limiting Parents’ Rights in Medical Decision Making, 8 AMA J. 
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arise in the medical treatment of children.  There have been several 
legal actions where the religious beliefs of a parent have come into 
conflict with medical decision making of a child.49  Generally, 
medical practitioners are obligated to provide treatment to pediatric 
patients if the treatment would reverse a life-threatening condition 
regardless of parental or guardian disagreement.50  This long-
standing concept is derived from the Supreme Court decision in 
Prince v. Massachusetts, when the Court concluded, “[p]arents may 
be free to become martyrs themselves.  But it does not follow they 
are free, in identical circumstances, to make martyrs of their 
children before they have reached the age of full and legal discretion 
when they can make that choice for themselves.”51  Considering this 
legal framework, the American Academy of Pediatrics (AAP) has 
created guidelines that assist in obtaining informed consent from 
parents as well as assent from children; the AAP states:  (1) 
“[p]ractitioners should seek the informed permission of parents 
before medical interventions (except in emergencies when parents 
cannot be contacted)” and (2) “[d]ecision-making involving the 
health care of older children and adolescents should include, to the 
greatest extent feasible, the assent of the patient as well as the 
participation of the parents and the physician.”52  As was noted in 
the federal guidelines, child assent should be solicited, but is not 
always legally required; as a result, it is usually left to IRB or ethics 
committee discretion.53  Assent is defined as “a child’s affirmative 
agreement to participate in research.”54  Notably, there is no specific 
age at which a child can assent; however, in practice, assent is 
sought from children above the age of six or seven.55  Instead, 
determining the capacity to assent is analyzed by a variety of 
 
OF ETHICS 676, 676 (2006); Koll, supra note 45, at 245–246 (discussing child organ 
donation and sterilization). 
 49. Black, supra note 48, at 676–677; Svoboda, supra note 46, at 84–88.  
 50. Danielle Chaet, The AMA Code of Medical Ethics’ Opinions Relevant to 
Patient- and Family-Centered Care, 18 AMA J. OF ETHICS 45, 45–46 (2016). 
 51. 321 U.S. 158, 170 (1944). 
 52. Comm. on Bioethics, Am. Acad. of Pediatrics, Informed Consent, Parental 
Permission, and Assent in Pediatric Practice, 95 PEDIATRICS 314, 315 (1995) 
(emphasis omitted) [hereinafter Am. Acad. of Pediatrics]. 
 53. CLINICAL RESEARCH INVOLVING CHILDREN, supra note 40, at 194–195 
(providing examples of how IRB has practiced discretion); NAT’L INST. OF HEALTH, 
NAT’L CANCER INST., CHILDREN’S ASSENT (June 22, 2016), https://www.cancer.gov/
about-cancer/treatment/clinical-trials/patient-safety/childrens-assent. 
 54. CLINICAL RESEARCH INVOLVING CHILDREN, supra note 40, at 157–158.  
 55. Id. at 156. 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factors such as:  psychological capacity, emancipation status, and 
whether the child is a “mature minor.”56 
The AAP requires that medical practitioners receive assent 
from capable pediatric patients by:  (1) helping the pediatric 
patients understand their condition, (2) explaining the tests and 
treatments they will undergo, (3) making an assessment of how 
much the pediatric patient is understanding, and (4) “[s]oliciting an 
expression of the patient’s willingness to accept the proposed 
care.”57  Furthermore, in regard to the expression of assent, the 
medical practitioner is required to weigh the child’s assent 
“seriously,” when considering appropriate medical care.58  In human 
subjects research there is disagreement as to whether child assent 
is always required.59  Notably, Ravitsky et al., argue the following 
in regard to assent in ovarian and testicular tissue 
cryopreservation, 
Child assent and parental consent should always be sought.  If 
the child is too young to give assent, no procedure involving 
more than minimal risk and not for their proven benefit should 
be permitted.  The consent should cover the possible use of the 
reproductive tissue, the duration of storage, and the disposal of 
the tissues in event of mental incapacitation or death.60 
Given the federal and medical framework within which IRBs 
are to analyze the ethical permissibility of experimental fertility 
cryopreservation techniques, one can begin discussing the ethical 
arguments in favor of and opposed to testicular and ovarian tissue 
cryopreservation in pre-pubertal children who cannot assent.61 
IV. Arguments in Opposition to Pre-Pubertal Ovarian and 
Testicular Tissue Cryopreservation Without Assent 
This section of the Article will address the four main 
arguments in opposition to pre-pubertal ovarian and testicular 
tissue cryopreservation with children who cannot assent:  (a) that 
these procedures are too medically risky, (b) that there is an 
impermissible conflict of interest in allowing parents and guardians 
 
 56. Id. at 324–25 (explaining that the mature minor rule means a child is 
“sufficiently mature to make (certain) health care decisions”); 45 C.F.R. § 46.408(a) 
(2016); IRB GUIDEBOOK, supra note 32, at 6–22. 
 57. Am. Acad. of Pediatrics, supra note 51, at 315.  
 58. Id. at 315–16.  
 59. D.S. Wendler, Assent in Paediatric Research: Theoretical and Practical 
Considerations, 32 J. MED. ETHICS 229, 230 (2006). 
 60. PENN CTR. FOR BIOETHICS, supra note 24, at 336.  
 61. Note, for the few children who will reach puberty prior to the age of assent, 
parents and guardians should also be prohibited from cryopreserving their gametic 
material, as most of the arguments in this Article remain persuasive. 
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to consent, (c) that these procedures create secondary ethical 
problems through issues of control over gametic material, and (c) 
that given the federal guidelines and the lack of proven success, it 
is questionable whether this research should be conducted 
altogether on children. 
a. Medical Risks 
One of the major ethical concerns with childhood ovarian and 
testicular tissue cryopreservation is the issue of subjecting 
individuals who cannot assent or consent to non-medically 
necessary procedures.  As will be discussed later, it is foreseeable 
that individuals will differ on determining the medical riskiness of 
ovarian and testicular tissue cryopreservation.  However, any 
additional medical procedure has potential medical consequences,62 
and each additional procedure performed on a child will increase 
their medical risks.63  There are several different types of medical 
risk associated with this form of fertility preservation:  (i) 
procedural risk, (ii) reproductive organ and gametic risk, (iii) re-
transplantation risk, and (iv) psychological risk. 
i. Procedural Risk 
Ovarian tissue is procured through laparoscopy surgery,64 
while testicular tissue is procured through removal of a testicle65 or 
through a biopsy.66  Testicular and ovarian tissue can either be 
procured simultaneously as the child is undergoing an unrelated 
medical procedure or the procedure can occur independently.67  
Children are required to undergo general anesthesia in order that 
the surgery can be performed to remove the tissue.68  The argument 
 
 62. Heidi Stevens, What Does the Future Hold for Kids with Cancer?, STAR TRIB. 
(June 7, 2012, 8:10 AM), http://www.startribune.com/what-does-the-future-hold-for-
kids-with-cancer/157559905/ (discussing fertility preservation for young children 
diagnosed with cancer).  
 63. Id. 
 64. Marie-Madeleine Dolmans et al., A Review of 15 Years of Ovarian Tissue 
Bank Activities, 30 J. ASSISTED REPROD. & GENETICS 305, 312 (2013). 
 65. U. PITTSBURGH, MANUAL OF OPERATIONS: TESTICULAR TISSUE 
CRYOPRESERVATION 5 (Sept. 2014), http://oncofertility.northwestern.edu/sites/
oncofertility/files/TTC_Manual_of_Operations.pdf.  
 66. CHILDREN’S HOSP. OF PHILA., supra note 20. 
 67. Lindsey Tanner, Kids with Cancer Get Futuristic Fertility Chance; 
Experimental Tissue-Freezing Even for Babies, U.S NEWS & WORLD REP. (Sep. 28, 
2017, 9:28 AM), http://health.usnews.com/health-news/news/articles/2015/08/11/
kids-with-cancer-get-futuristic-chance-at-saving-fertility. 
 68. Mark F. H. Brougham & W. Hamish B. Wallace, Male Infertility Following 
Childhood Cancer: Special Considerations for Fertility Preservation in Children, in 
FERTILITY PRESERVATION IN MALE CANCER PATIENTS 164 (John P. Mulhall et al. 
2018] Cryopreservation 105 
in favor of a simultaneous procedure is that the child does not need 
to undergo an additional anesthesia.  This is especially important 
in young children, as there is significant concern about the effects 
of anesthesia on their brains.69  Studies have shown “an association 
between learning problems and multiple exposures to anesthesia 
early in life—though not single exposures.”70  However, there are 
also concerns about keeping a child anesthetized for a lengthier 
period of time to complete the additional procedure, as there is some 
evidence that suggests spending more time under anesthesia can 
negatively impact recovery.71  Usually, the risk of lengthier 
anesthesia is less than multiple anesthesias.72  Notably, there has 
been at least one death reported due to an anesthesia complication 
during ovarian tissue cryopreservation.73  In addition to anesthetic 
concerns, ovarian tissue retrieval can cause “discomfort, pain, 
bleeding from cicatrices,”74 and urinary tract infection.75  Another 
medical concern is whether ovarian or testicular tissue 
cryopreservation may compromise medically necessary care for the 
child, for example, if the child were to contract an infection and then 
not be eligible to undergo their medically necessary oncology 
treatments because of a weakened immune system. 
ii. Reproductive Organ and Gametic 
Tissue Risk 
There is both a risk to the tissue that is cryopreserved and a 
risk of damaging reproductive organs or material that are not 
surgically removed.  There is a concern that testicular tissue 
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retrieval may cause trauma to the testicle.76  Similarly, it is 
foreseeable that there could be trauma to the ovary (a concern with 
ova retrieval).77  In one study reporting on whole ovary removal, 
twenty-seven percent of individuals reported complications due to 
the procedure, including the need to have “additional surgeries for 
cutaneous infections or bladder lesions.”78  Furthermore, 
cryopreservation can damage gametes through the process of being 
cryopreserved and then thawed.79  Additionally, cryopreserving a 
full ovary can “fracture . . . the ovarian pedicle, preventing 
successful vascular transplantation; fracture of the surface of the 
ovary as a whole, which then provides an interface for ice crystal 
formation; inconsistent permeation of the cryoprotectant; and 
potential for ice crystal formation in the ovarian pedicle or ovary 
during warming.”80 
iii. Re-transplantation Risk 
Another major concern about the reimplantation of 
cryopreserved gametic tissue is the potentiality of reintroducing 
cancerous cells into the patient.81  This is a concern for both 
testicular82 and ovarian83 tissue cryopreservation.  Typically, 
testicular and ovarian tissue cryopreservation is sought prior to 
gonadotoxic treatments to prevent damage to the tissue, but as a 
result, there may be cancerous tissue removed simultaneously with 
the gametic tissue.84  The type of cancer that the patient suffers 
from may impact whether there is the possibility of re-
transplanting cancerous cells from their gametic tissue.85  Tissue 
taken from individuals who suffer from blood-borne cancers, such 
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as leukemia, have tested positive for cancerous cells.86  In one study, 
tissue taken from breast cancer patients did not indicate cancerous 
cells, but the researchers cautioned that more screening was 
necessary.87  Another study concluded that the possibility of 
reintroducing cancer was high in leukemia patients, moderate for 
gastrointestinal cancer patients, and low for Hodgkin’s and Non-
Hodgkin’s Lymphoma, breast cancer, gynecological cancers, and 
sarcomas of the bone and connective tissue.88 
iv. Psychological Risk 
In addition to the physiological risks discussed above, it is 
worth noting the potential psychological impact ovarian and 
testicular tissue cryopreservation may have.  This is a risk that can 
affect the child, the parents, and guardians who consent to the 
procedure.89  There are three main concerns:  (1) individuals will 
experience great emotional loss if the procedures do not work; (2) 
individuals may build up unrealistic faith and reliance upon the 
idea of using this gametic material in the future; and (3) if there are 
complications, the negative emotional impact this may have on the 
parents or guardians who consented to the procedure.  Parents and 
guardians as well as the child are at risk for experiencing loss if 
these procedures are unsuccessful—the loss of potential genetically-
related children and grandchildren.  Furthermore, reliance upon 
frozen gametic tissue may impact choices and decisions cancer 
survivors make in their future, such as delaying procreation.  
Lastly, if there are negative complications, or if these procedures 
impact a child’s medically-necessary treatment, it is foreseeable 
that parents and guardians may experience guilt or remorse. 
However, clinical psychologist Dan Shapiro of the Humanities 
Department at Pennsylvania State University, College of Medicine, 
disagrees with many of these psychological concerns.  Shapiro 
argues that “[g]iven what we know about the psychological 
challenges of infertility, which is enormously stressful—about as 
stressful as having a chronic pain condition—and the exciting 
promise of ovarian cryopreservation techniques, I think parents of 
 
 86. See Dolmans, supra note 64, at 312; see also Bahadur, supra note 76, at 1418 
(discussing the risk of such transmission and trial evidence from mice). 
 87. Dolmans, supra note 64, at 312. 
 88. Mikkel Rosendahl, Tine Greve & Claus Yding Andersen, The Safety of 
Transplanting Cryopreserved Ovarian Tissue in Cancer Patients: A Review of the 
Literature, 30 J. ASSISTED REPROD. & GENETICS 11, 11 (2013). 
 89. Stevens, supra note 62. 
108 Law & Inequality [Vol. 36: 95 
children facing cancer treatments would be mistaken not to try 
this.”90 
From a utilitarian ethical analysis, conducting these 
procedures in pre-pubertal children who cannot assent to these 
risks is ethically impermissible.  Parents and guardians should not 
risk the life and health of their children for the mere possibility that 
their children may be able to use this tissue in the future.  
Moreover, as was mentioned earlier in this Article, gonadotoxic 
treatments do not necessitate infertility.  The most significant 
counter-argument to the medical-risk concern is that researchers 
and medical practitioners could mitigate some of the risk by 
following a criterion to determine which patients are the best 
candidates for tissue cryopreservation.91  While selection criteria 
will limit who these procedures will be offered to, it does not address 
the fact that parents and guardians should not be risking the health 
and life of their children for a medically unnecessary procedure.  If 
a child can and is willing to assent to this procedure, then medical 
practitioners should engage in a conversation about the risks and 
potential outcomes, but parents and guardians should not be 
permitted to subject their already-compromised child to additional 
medical risk, even at the risk of infertility.  Potential procreative 
capability does not outweigh the health and life of the child. 
b. Conflict of Interest 
One of the major ethical concerns about cryopreservation is 
whether parents and guardians who consent to their pre-pubertal 
children undergoing these procedures have a conflict of interest.  
The conflict argument stems from the concern that parents, by 
cryopreserving their children’s ovarian or testicular tissue, are 
either (1) acting in their self-interest in that they want genetically-
related grandchildren, or (2) that they are imposing their preference 
of procreation on their children.  Regarding the first concern, the 
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parent or guardian may have a great desire to have grandchildren 
and therefore may be cryopreserving their child’s ovarian or 
testicular tissue so that they will be able to fulfill that desire to 
become a grandparent.  The second concern is that parents or 
guardians will impose a sense of duty and pressure upon their child 
to eventually procreate in the future if they cryopreserve their 
ovarian or testicular tissue. 
There are no persuasive counter-arguments to the concern 
that parents or guardians may be acting in their own self-interest, 
as it is nearly impossible to determine whether the parent or 
guardian simply wants to provide an option for future fertility for 
their child or if they are acting based upon their desire to become a 
grandparent.  It is arguable that parents and guardians may not 
even realize that they are acting in their own self-interest, as they 
are too emotionally invested in their child’s fertility.  Notably, in the 
testimonies of parents who are a part of the experimental work 
being done at the University of Pennsylvania, many of the parents 
reiterated that they wanted to be grandparents.92  Moreover, 
medical staff state that it is part of their job to “let [patients] know 
why [ovarian and testicular tissue cryopreservation] is important, 
and to . . . set the scene,” even when the children stated that they 
did not know if they wanted to have kids.93 
Furthermore, allowing parents and guardians to consent 
without a child’s assent imposes certain values about procreation 
on children, when many individuals do not wish to procreate or may 
have different values regarding how they wish to build their 
families.  Quinn et al., argued that these concerns are not justified 
because a child’s values are already impacted by their upbringing, 
including the decision to have children, and that a child may feel 
pressure regardless of the situation to abide by their parent’s 
wishes.94  However, these counterarguments are unconvincing, as 
these children will eventually have to make decisions whether to 
implant, destroy, or donate their cryopreserved ovarian or 
testicular tissue, a situation they may not have desired to be in.  
Moreover, they may feel even more compelled to procreate because 
of the burden their families underwent to cryopreserve their 
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ovarian or testicular tissue.  I do not intend to argue that procuring 
a child’s assent will alleviate all of these conflicting concerns, as 
parents or guardians may still pressure their children to assent, but 
arguably, based upon the AAP’s ethical guidelines stated earlier in 
this Article, assent will provide a better opportunity that a child’s 
wishes will be abided by. 
c. Decision-Making Concerns Regarding Cryopreserved 
Ovarian and Testicular Tissue 
Another ethical concern is the issue of “control” of the ovarian 
or testicular tissue.  The control issue has several components:  (1) 
control over the tissue while the child is minor, (2) disposition of 
tissue, (3) claims to the tissue, and (4) addressing conflict.  In regard 
to the first concern, if a child has the ability to assent, they would 
have the ability to partake in the decision-making process regarding 
their gametic tissue.  However, if the child cannot assent, who 
should have the ability to make decisions over the gametic 
material?  Will the material be cryopreserved until the child can 
assent?  Additionally, it is unclear if the tissue would be re-
transplanted when the child is healthy, when they can assent, or 
when they have reached majority.  Regarding the second concern, 
as was mentioned above, Ravitsky et al. argue that the tissue needs 
to be destroyed if the child dies or is incapacitated.95  Not only is 
permitting a parent or guardian to consent to destroying another 
independent individual’s gametic material ethically problematic, it 
is foreseeable that a child may want their tissue donated and not 
destroyed. 
There is also a potential concern that a parent or guardian 
may have a claim to the gametic material if the child dies.  There 
are already controversies that occur when parents of deceased 
children stake a claim to the gametic material of their children.96  
Lastly, if the child cannot assent, it is unclear how conflict will be 
dealt with.  The Office of the Human Research Protection Program 
states that when there is a conflict, a child should not be part of a 
study until the conflict is resolved.97  But what happens if parents 
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and guardians do not agree after the tissue is cryopreserved?  The 
current solution for conflict surrounding gametic material has been 
litigation.  A simpler solution would be to conduct these 
experimental procedures only on children who can assent. 
d. Should We Be Doing This Research? 
Fundamentally, underlying all of the opposition arguments to 
pre-pubertal ovarian and testicular tissue cryopreservation without 
a child’s assent is the question of whether this type of experimental 
research is permissible at this time.  Determining whether pre-
pubertal ovarian and testicular tissue cryopreservation should be 
conducted requires an analysis of the four federal guidelines 
discussed in Part II of this Article.  Based upon potential medical 
risks stated in Part IV, Section a of this Article, it is arguable that 
ovarian and testicular tissue cryopreservation does not fit in the 
category of research that is of minimal risk, as subjecting a child to 
these risks seems greater than the risks a child would encounter in 
daily life or during routine medical tests.98 
If one considers these fertility preservation procedures as 
research that involves greater than minimal risk, then the next 
question is whether fertility preservation provides a direct benefit 
to the child.  According to the IOM, direct benefit means that there 
is a “tangible positive outcome”; a likely conclusion from the 
discussion in Part IV of this Article is that there is no “tangible 
positive outcome,” there is only a mere possibility of a positive 
outcome.  As a result, ovarian and testicular tissue cryopreservation 
would be subject to the additional requirements of Category 3 
research.  It is unclear whether pre-pubertal ovarian and testicular 
tissue cryopreservation could withstand the Category 3 
requirement; “[t]he intervention or procedures present experiences 
to subjects that are reasonably commensurate with those inherent 
in their actual or expected medical . . . situations.”99  Arguably, the 
cryopreservation procedure is not something a child experiences 
with their expected oncology care.  Moreover, if one considers these 
fertility preservation techniques to be outside the scope of 
Categories 1, 2, and 3 of the federal regulations, then pre-pubertal 
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fertility cryopreservation is subject to significantly higher 
standards.  The research would have to alleviate “a serious problem 
affecting the health or welfare of children” and the Secretary would 
have to review the research.100  It is extremely unlikely that pre-
pubertal fertility cryopreservation would meet this standard. 
Determining whether these procedures follow appropriate 
federal guidelines and determining what category, if any, they are 
governed by greatly impacts whether these procedures should be 
ongoing.  As mentioned earlier, Ravitsky et al. state that 
experimental procedures that are greater than minimal risk and 
that have no proven benefit should not be conducted without a 
child’s assent.101  Conceivably, the IRBs at the University of 
Pennsylvania and CHOP have concluded that ovarian and 
testicular tissue cryopreservation is of minimal risk, or of greater 
than minimal risk with a direct benefit to the child.  However, 
considering the lack of successful data and the minimal animal 
trials, especially in the situation of testicular tissue removal,102 it is 
imperative to question whether pre-pubertal ovarian and testicular 
tissue cryopreservation should be conducted at this time, regardless 
of assent. 
V. Counter-Arguments in Favor of Pre-Pubertal Ovarian 
and Testicular Tissue Cryopreservation Without Assent 
This section of the Article will address the three most 
compelling arguments in favor of pre-pubertal ovarian and 
testicular tissue cryopreservation without assent:  (a) these 
procedures will potentially preserve a child’s fertility; (b) parents 
and guardians have a moral responsibility to safeguard an “open 
future” for their children; and (c) these experimental procedures 
should be conducted for the advancement of science. 
a. Potentially Preserving Future Fertility 
The most persuasive argument in favor of cryopreservation of 
pre-pubertal ovarian or testicular tissue is that these procedures 
may potentially preserve fertility for children who may become 
infertile due to gonadotoxic treatment.  Studies have shown that 
individuals who have been treated for childhood cancers have an 
increased risk of infertility.103  Male survivors rank testicular 
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dysfunction as one of the major side effects of oncology treatments, 
while female survivors have experienced damage to their ovarian 
tissue and uterine function.104  Determining the certainty of 
infertility in these situations is unpredictable and difficult, as 
infertility symptoms usually manifest much later in an individual’s 
life.  As a result, determining whether infertility is a direct result of 
gonadotoxic treatments or other secondary factors such as age is 
onerous and sometimes inconclusive.105  Moreover, oncology 
treatments themselves vary and as a result will have different 
gonadotoxic severities.106  Nonetheless, proponents of these 
procedures argue that the increased risk of infertility is sufficient 
reason to undertake these preventative measures.  Additionally, 
there have been successful pregnancies after re-transplantation of 
ovarian tissue into women who have had their tissue cryopreserved, 
and animal trials have shown success with re-transplantation of 
testicular tissue.107 
However, even though there is the potentiality of preserving 
fertility by cryopreserving ovarian or testicular tissue, there are two 
significant problems with this argument.  First, there is no 
guarantee that re-transplantation of ovarian or testicular tissue 
later in life will result in fertility, as there are risks associated with 
removal, cryopreservation, and re-transplantation.  Initially, 
ovarian tissue cryopreservation had a low success rate because the 
cryopreserving process damaged the tissue.108  Eventually a new 
type of “freezing” called vitrification was developed in order to 
prevent damaging crystallization.109  While vitrification proved 
more successful, the exact number of how many women have been 
re-implanted with their ovarian tissue remains unknown.110  
Therefore, the success rate may actually be inconsequential 
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compared to risking gonad and gametic tissue damage.  Second, 
refraining from cryopreserving ovarian or testicular tissue of 
children undergoing gonadotoxic treatments does not necessitate 
that these children will be infertile, as there are childhood cancer 
survivors who become pregnant.111  In fact, some studies suggest 
that while female cancer survivors may take longer to get pregnant 
than sisters who have not had cancer, two-thirds of female cancer 
survivors initially deemed infertile eventually became pregnant, 
becoming so just took longer than their siblings.112  Furthermore, 
“fertility cannot be assessed before puberty”; therefore, the effects 
of oncology treatments are unclear.113  Lastly, this argument does 
not take into account the potential of less invasive fertility 
advancements that may be available in the future, nor does it 
account for other options in creating a family, such as adoption or 
the use of donor gametes. 
b. Moral Responsibility to Give Children All Options 
Parents and guardians have a moral and legal duty to act in 
the best interest of their child.  Defining what is considered to be in 
the best interest of a child is extremely difficult, especially in the 
area of medical decision-making.  As a result, it is arguable that 
parents and guardians of children experiencing gonadotoxic 
treatments should, or are required to, cryopreserve their children’s 
ovarian or testicular tissue as part of their duty as parents and 
guardians.  The argument in “bioethical literature [is coined] as a 
‘right in trust,’ to be safeguarded until the child reaches 
adulthood.”114  The argument originally stems from the bioethical 
and philosophical concept of an “open future.”115  An “open future,” 
originally posited by the academic Joel Feinberg, means that there 
are a “set of moral rights children possess that are derived from the 
autonomy rights of adults.”116  As a result, children have the right 
to future fertility because as an adult they would have the capacity 
to make the autonomous decision whether to procreate.  Arguably, 
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fertility is a component of normal human functioning, and as 
Professor Norman Daniels would argue, “protecting normal 
functioning contributes to protecting opportunity.”117  Thus, 
proponents argue that even if a child cannot assent to the 
procedure, it is the obligation of the parent or guardian to consent.  
Furthermore, the extension of this argument is that parents could 
be deemed irresponsible or neglectful if they do not provide this 
option for children, because of the burden of potential infertility.118 
While parents and guardians should provide opportunities 
that are beneficial to their children, it is unconvincing to suggest 
that they would be morally required to provide an experimental 
medical treatment to their children.  Additionally, if one follows this 
argument in its entirety, why would ovarian and testicular tissue 
cryopreservation be only limited to individuals who are 
experiencing gonadotoxic treatment?  There is an argument to be 
made that if parents have an obligation to create and maintain an 
“open future” for their children, they should provide fertility 
preservation mechanisms at an early age because (1) there are 
many causes of infertility that a child may face in their future, and 
(2) if ovarian and testicular tissue cryopreservation happen while 
the child is young, they will have no recollection of the procedures.  
Most would agree that subjecting an otherwise healthy child to an 
unnecessary medical procedure is ethically problematic.  
Realistically, practical financial considerations or religious or 
philosophical beliefs will prevent parents from permitting ovarian 
and testicular tissue cryopreservation for their children who are 
experiencing gonadotoxic treatments; therefore, the moral 
responsibility argument is unconvincing. 
c. Advancement of Science as a Societal Imperative 
As was mentioned earlier in this Article, the federal guidelines 
may permit otherwise not-approvable human subject research 
using children if it “presents an opportunity to understand, prevent, 
or alleviate a serious problem affecting the health or welfare of 
children.”119  There is an argument that even if cryopreservation of 
a specific child’s gametic tissue were unsuccessful in being re-
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transplanted, developing these fertility preservation techniques 
assists in the advancement of science.  Moreover, improving the 
quality of life of cancer survivors is a beneficial social good.  Unlike 
adult-onset cancer, pediatric patients have approximately an eighty 
percent long-term survivorship rate, which plausibly warrants 
development of medical care for their future.120 
However, as I argued before, it is unlikely that pre-pubertal 
ovarian and testicular tissue cryopreservation will meet the 
requirements for research in Category 4.  A part of the requirement 
for Category 4 research is that the IRB must “find[] that the 
research presents a reasonable opportunity to further the 
understanding, prevention, or alleviation of a serious problem 
affecting the health or welfare of children.”121  It is unlikely to do so, 
because while infertility is a serious medical concern, potential 
infertility would not meet this threshold in consideration of the 
potential medical risks children would undergo during this 
research.  Developing fertility preservation techniques for children 
who experience gonadotoxic treatments is an ethically worthwhile 
venture.  However, under a utilitarian ethical framework, 
subjecting children, especially children who cannot assent, to 
medically risky research that may not directly benefit them, simply 
for the potential of preserving another child’s fertility, is ethically 
impermissible. 
Conclusion 
While the intention of ovarian and testicular tissue 
cryopreservation in pre-pubertal children is to benefit children 
undergoing gonadotoxic treatments, it is ethically too problematic 
to be permissible.  The potential benefit of preserving fertility does 
not outweigh the potential medical consequences and the conflicts 
of interest, nor does it address potential future conflicts that will 
result due to the cryopreserved material.  Assent, while not 
alleviating all concerns, will mitigate many of them.  Moreover, the 
federal guidelines and the AAP both highly encourage seeking 
assent when conducting medical and experimental research on 
children.  Finally, the counter-arguments are unconvincing given 
the potential risks to which children are exposed.  As a result, 
ovarian and testicular tissue cryopreservation in pre-pubertal 
children without assent should not continue at this time. 
 
 
 120. Quinn, supra note 94, at 38. 
 121. § 46.407. 
